Abstract:BACKGROUND Acute liver failure (ALF) is a significant and complex hepatic insult that may rapidly progress to life-threatening conditions. Recently, menstrual blood stem cells (MenSCs) have been identified as a group of easily accessible mesenchymal stem cells with the advantages of non-invasive acquisition, low immunogenicity, a greater capacity of self-renewal and multi-lineage differentiation, making them promising candidates for stem cell-based therapy to revolutionize the treatment strategies for liver failure. AIM To investigate the therapeutic potential of MenSCs for treating ALF in pigs and to dynamically trace the biodistribution of transplanted cells. METHODS MenSCs were labeled in vitro with PKH26, a lipophilic fluorescent dye. The treatment group received immediate transplantation of PKH26-labelled MenSCs (2.5 × 106/kg) via the portal vein after D-galactosamine injection, and the control group underwent sham operation. The survival time, liver function, and hepatic pathological changes were compared between the two groups. Three major organs (liver, lungs and spleen) were extracted from animals and imaged directly with the In vivo Imaging System (IVIS) at the predetermined time points. The regions of interest were drawn to quantify the cell uptake in different organs. RESULTS The labelling procedure did not affect the morphology, viability or multipotential differentiation of MenSCs. Biochemical analysis showed that the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and prothrombin time (PT) measured at selected time points 24 h after transplantation were significantly decreased in the treatment group (P < 0.05). The survival time of ALF animals was prolonged in the treatment group compared with the control group (75.75 ± 5.11 h vs 53.75 ± 2.37 h, log rank, P < 0.001). The liver pathological tissue in the MenSC treatment group showed obviously increased numbers of remaining hepatocytes and a comparatively slight necrotic degree and area. In addition, the IVIS imaging revealed that PKH26-positive MenSCs were clearly retained in the liver initially and then diffused through the systemic circulation. Interestingly, the signal intensity in the liver increased obviously at 36 h, which corresponded to the biochemical result that liver function deteriorated most rapidly at 24 - 36 h. CONCLUSION Our study demonstrates the therapeutic efficacy and homing ability of transplanted MenSCs in a large animal model of ALF and suggests that MenSC transplantation could be a promising strategy for treating ALF.

Fully Bioactive Nanodrugs: Stem Cell-Derived Exosomes Engineered with Biomacromolecules to Treat CCl 4 - and Extreme Hepatectomy-Induced Acute Liver Failure

Cell therapy in end-stage liver disease: replace and remodel

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Microfluidic Fabrication of MicroRNA-Induced Hepatocyte-Like Cells/Human Umbilical Vein Endothelial Cells-Laden Microgels for Acute Liver Failure Treatment

Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure.

Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure

A Biomimetic Multifunctional Nanoframework for Symptom Relief and Restorative Treatment of Acute Liver Failure

Human Endoderm Stem Cells Reverse Acute Liver Failure Through Cystatin SN-Mediated Inhibition of Interferon Signaling

Effects of Plasma from Patients with Acute on Chronic Liver Failure on Function of Cytochrome P450 in Immortalized Human Hepatocytes.

A Simple and Efficient Strategy for Cell-Based and Cell-Free Based Therapies in Acute Liver Failure: Hucmscs Bioartificial Liver

Treatment of Acute Hepatic Failure in Mice by Transplantation of Mixed Microencapsulation of Rat Hepatocytes and Transgenic Human Fetal Liver Stromal Cells.

3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment

Extra-corporeal non-liver transplant therapies for acute liver failure: Focus on plasma exchange and continuous renal replacement therapy

Therapeutic Potential of Menstrual Blood Stem Cells in Treating Acute Liver Failure

Human endoderm stem cells reverse inflammation-related acute liver failure through cystatin SN-mediated inhibition of interferon signaling

Acute Liver Failure and Bioartificial Liver Support

Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis

Bioinspired menstrual blood‐derived stem cells‐conditioned medium/polymersome nanoparticles for the treatment of carbon tetrachloride‐induced acute liver failure in mice

Stem Cell-Based Strategies: The Future Direction of Bioartificial Liver Development

Framework nucleic Acid-MicroRNA mediated hepatic differentiation and functional hepatic spheroid development for treating acute liver failure

Mesenchymal Stem Cell Therapy in Acute Liver Failure